Ocular Therapeutix Inc. said the therapeutic area has plenty of room for its newly approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg for postoperative eye pain along with Eyepoint Pharmaceuticals Inc.'s single-dose, sustained-release, intracameral Dexycu (dexamethasone intraocular suspension) 9 percent, granted U.S. marketing clearance earlier this year for inflammation after surgery.